in EudraCT. The report credits three efforts for the UK's superior compliance: pressure from Parliament, research funders, and health integrity and transparency groups, including TranspariMED. It should be noted, however, that improvements in reporting behaviour in the UK have been relatively recent (for some, since November, 2018) and have been made by only a small number of universities. Thus, maintaining and enforcing compliance in a larger number of universities is critical, and in the long term, especially as the number of registered clinical trials increases every year.
Who is responsible for holding universities (and all trial sponsors) accountable for updating these dataand how? The FDA Amendments Act authorises fines of US$10 000 for violations, but has yet to issue one (as of October, 2018). Clinical trial funders can threaten to withdraw support, but it is unclear whether this penalty has ever been implemented. Perhaps if there were tougher mechanisms to enforce trial reportingeg, a national or an international watchdog, with the authority to act and also with the necessary infrastructure, personnel, and budget to do so-then trial reporting would improve. Punishing offenders is one way to recoup wasted effort, confirm data reporting, and deter failures to report, but it discounts positive measures that encourage trial sponsors to behave pro-actively to keep registries up to date.
Consideration of the reasons why universities fail to update summary trial data at the end of a trial, might provide clues towards a solution. Oncology triallists should take the lead here. According to the latest WHO data, oncology trials represent the largest proportion of all clinical trials being done across the medical continuum. Universities already face many hurdles when undertaking clinical trials, including cost, workload demands, and bureaucracy, which are already overburdensome. Could automated email reminders from the registry to upload summary data be a simple solution that has been overlooked? Regardless of the increased burden, a combination of efforts is needed to improve public reporting of trial results, and immediate and robust action is necessary to eliminate research waste, improve the overall transparency of medical research, and fulfil our ethical obligations to patients. ■ The Lancet Oncology 
